Compare VRAX & MBOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRAX | MBOT |
|---|---|---|
| Founded | 2013 | 2010 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 972.3K | 73.2M |
| IPO Year | 2021 | 2000 |
| Metric | VRAX | MBOT |
|---|---|---|
| Price | $0.61 | $0.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.38 |
| AVG Volume (30 Days) | 537.1K | ★ 861.4K |
| Earning Date | 11-20-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 60.27 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $116,887.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $377.83 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.10 | $0.93 |
| 52 Week High | $13.19 | $2.86 |
| Indicator | VRAX | MBOT |
|---|---|---|
| Relative Strength Index (RSI) | 21.31 | 39.89 |
| Support Level | $0.15 | N/A |
| Resistance Level | $1.57 | $1.18 |
| Average True Range (ATR) | 0.17 | 0.08 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 10.47 | 10.54 |
Virax Biolabs Group Ltd is a biotechnology company focused on the detection of immune responses and the development of immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. The company's principal development activities are centered on T cell-based in vitro diagnostics and immune profiling. The company's flagship product candidate, ViraxImmune, is an in-development T cell-based assay and immune profiling platform intended to support the assessment of immune dysfunction, initially in PAIS indications.
Microbot Medical Inc is a medical device company specializing in the research, design, and development of next-generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. Using its LIBERTY technological platform, the company has developed the LIBERTY Endovascular Robotic Surgical System, a fully disposable robot for various endovascular interventional procedures. The company has a single operating and reportable segment, which is the development of robotic devices for endoluminal surgery.